



## **Converting from Intravenous to Oral Antibiotic Therapy**

During an acute illness or hospital stay, residents may begin parenteral antibiotic therapy to combat a significant infection. As their clinical condition begins to improve, many residents may be candidates for a conversion from IV to oral (PO) antibiotic therapy. Appropriate conversion from IV to PO antibiotic therapy can result in several significant benefits:

- Reducing the risk of intravascular catheter or line infection
- Improved patient comfort and mobility
- Decreased length of stay
- Reduced nursing preparation and administration time
- Reduced medication and supply costs

Consider the following criteria to identify residents that may be suitable candidates for an IV to PO conversion.

<u>IV to PO Conversion Possible If:</u> (ALL Criteria Should be met to consider IV $\rightarrow$ PO Conversion)		Do NOT convert from IV to PO if: (Continue IV Therapy if ANY of the below criteria are met)		
	Received > 48 hours of IV antibiotic therapy		Serious life threatening infection- meningitis, endocarditis, osteomyelitis, septicemia, etc.	
	Improving WBC and differential counts		Abnormal WBC count that is not improving	
	Resident clinically improving		Severely immunocompromised (s/p transplant)	
	Afebrile for at least 24 hours ( temperature ≤ 100°F or 38 °C)		Fever > 38°C (100°F)	
	Heart Rate < 100 BPM		Heart Rate ≥ 100 BPM	
	Systolic BP > 90 mmHg		Systolic BP ≤ 90 mmHg	
	Respiratory Rate <24 breaths per minute		Respiratory Rate ≥ 24 breaths per minute	
	No vomiting, diarrhea, or NPO	Nausea, vomiting, diarrhea		
	Taking other medications and food orally		Difficulty swallowing, or GI malabsorption/obstruction	



Listed below are a number of commonly used antibiotics known to have virtually equivalent bioavailability when given by either the IV or PO routes. However, the final decision to convert a resident from IV to PO therapy should be based on the individual resident's clinical condition and available laboratory data. Once switched, residents should be closely monitored for changing conditions over the next 24-48 hours.

	Brand name	Deventeral Deve	PO Conversion
Medication		Parenteral Dose	(tablet or capsule)
Azithromycin	Zithromax	250 mg IV once daily	250 mg PO once daily
Azitinomycin	Zitinomax	500 mg IV once daily	500 mg PO once daily
	Cipro	200 mg IV once daily	250 mg PO once daily
		200 mg IV Q12H	250 mg PO Q12H
Ciprofloxacin		400 mg IV once daily	500 mg PO once daily
		400 mg IV Q12H	500 mg PO Q12H
		400 mg IV Q8H	750 mg PO Q12H
Clindomusin	Cleocin	300mg IV Q6-8H	150 mg PO Q6-8H
Clindamycin	Cleocin	600 mg IV Q6-8H	300 mg PO Q6-8H
Doxycycline	Doxy	100 mg IV Q12H	100 mg PO Q12H
	Diflucan	100 mg IV once daily	100 mg PO once daily
Fluconazole		200 mg IV once daily	200 mg PO once daily
		400 mg IV once daily	400 mg PO once daily
		250 mg IV once daily	250 mg PO once daily
Levofloxacin	Levaquin	500 mg IV once daily	500 mg PO once daily
		750 mg IV once daily	750 mg PO once daily
Linezolid	Zyvox	600 mg IV Q12H	600 mg PO Q12H
	Flagyl	250 mg IV Q6H	250 mg PO Q6H
Metronidazole		500 mg IV Q6H	500 mg PO Q6H
		500 mg IV Q8-12H	500 mg PO Q8-12H
Trimethoprim/sulfamethoxazole	methoprim/sulfamethoxazole Bactrim 800 mg/160 mg IV Q12H		800 mg/160 mg PO Q12H

## References

- 1. Algorithms Promoting Antimicrobial Stewardship in Long Term care. BJ Zarowitz et al. JAMDA. 2016; (17): 173-178.
- 2. Considerations for PO to IV dose conversions. Pharmacist's Letter/Prescriber's Letter. 2010;26(9):260912.
- 3. Kuti JL, Le TN, Nightingale CH, Nicolau DP, Quintiliani R. Pharmacoeconomics of a pharmacist-managed program for automatically converting levofloxacin route from IV to oral. *Am J Health-Syst Pharm*. 2002; 59(22):2209-2215.
- 4. Mertz D, Koller M, Haller P, et al. Outcomes of early switching from intravenous to oral antibiotics on medical wards. *J Antimicrob Chemother*. 2009;64(1):188-199.